Recordati Industria Chimica e Farmaceutica S.p.A.'s latest marketcap:
As of 07/05/2025, Recordati Industria Chimica e Farmaceutica S.p.A.'s market capitalization has reached $13.13 B. According to our data, Recordati Industria Chimica e Farmaceutica S.p.A. is the 1528th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 13.13 B |
| Revenue (ttm) | 2.84 B |
| Net Income (ttm) | 492.13 M |
| Shares Out | 206.3 M |
| EPS (ttm) | 2.35 |
| Forward PE | 22.35 |
| Ex-Dividend Date | 05/19/2025 |
| Earnings Date | 07/29/2025 |
Recordati Industria Chimica e Farmaceutica S.p.A.'s yearly market capitalization.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 07/05/2025 | €13.13 B | 6.67% | 1528 |
| 12/30/2024 | €10.35 B | 3.04% | 1623 |
| 12/29/2023 | €10.04 B | 26.16% | 1472 |
| 12/30/2022 | €7.96 B | -31.72% | 1720 |
| 12/30/2021 | €11.66 B | 24.95% | 1437 |
| 12/30/2020 | €9.33 B | 21.69% | 1459 |
| 12/30/2019 | €7.67 B | 21.54% | 1528 |
| 12/28/2018 | €6.31 B | -17.06% | 1514 |
| 12/29/2017 | €7.61 B | 37.53% | 1409 |
| 12/30/2016 | €5.53 B | 12.31% | 1684 |
Company Profile
About Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A., along with its subsidiaries, is a global pharmaceutical company engaged in the research, development, production, and sale of pharmaceuticals. The company operates in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and other international markets.
Business Segments
- Specialty and Primary Care – Focuses on a broad range of therapeutic areas.
- Rare Diseases – Specializes in treatments for uncommon medical conditions.
Key Products and Developments
- Rare Disease Treatments: REC 0545 (maple syrup urine disease), Isturia (Cushing’s syndrome), Cystadrops (corneal cystine deposits), Carbaglu (hyperammonemia), Qarziba (neuroblastoma), and Fortivda (renal cell carcinoma).
- Oncology & Hematology: Sylvant (Castleman disease), ENJAYMO (cold agglutinin disease), Eligard (prostate cancer).
- Cardiovascular & Hypertension: Zanidip, Zanipress, Logimax, and Seloken.
- Urology & Men’s Health: Urorec and Avodart (benign prostatic hyperplasia).
- Infectious & Inflammatory Diseases: Polydexa, Isofra, Otofa (ENT infections), Tergynan (gynecological infections), Lomexin (dermatological infections).
- Gastrointestinal & Dietary: CitraFleet, Phosphosoda (bowel cleansers), Magnesio Supremo (dietary supplement).
- Other Treatments: Procto-Glyveno (hemorrhoids), Reaglia (schizophrenia), Hexaspray (throat spray).
Pipeline & Research
The company is actively developing new treatments, including:
- REC 0559 for neurotrophic keratitis.
- Pasireotide (Phase II trial for post-bariatric hypoglycemia).
Company Background
Founded in 1926, Recordati is headquartered in Milan, Italy, and has established itself as a key player in the global pharmaceutical industry.
Frequently Asked Questions
-
What is Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT-REC) current market cap?As of 07/05/2025, Recordati Industria Chimica e Farmaceutica S.p.A. (including the parent company, if applicable) has an estimated market capitalization of $13.13 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Recordati Industria Chimica e Farmaceutica S.p.A. (BIT-REC) rank globally by market cap?Recordati Industria Chimica e Farmaceutica S.p.A. global market capitalization ranking is approximately 1528 as of 07/05/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.